Nov 07, 2025 • Zacks Commentary
BULLISH
Can Aurinia ( AUPH ) Run Higher on Rising Earnings Estimates?
Aurinia Pharmaceuticals (AUPH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Nov 04, 2025 • Zacks Commentary
NEUTRAL
Aurinia Pharmaceuticals ( AUPH ) Surpasses Q3 Earnings and Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of +43.75% and +7.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 03, 2025 • Benzinga
NEUTRAL
FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse - Aurinia Pharmaceuticals ( NASDAQ:AUPH )
George Tidmarsh, head of the Food and Drug Administration's ( FDA ) drug center, resigned Sunday following allegations that he misused his regulatory power to financially harm a former business associate.
Aug 04, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Aurinia ( AUPH ) Upgraded to Buy: Here's What You Should Know
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aug 01, 2025 • Motley Fool
SOMEWHAT-BULLISH
Aurinia ( AUPH ) Q2 Revenue Jumps 22%
Aurinia Pharmaceuticals ( NASDAQ:AUPH ) , a biopharmaceutical company focused on therapies for autoimmune diseases, released its second-quarter 2025 earnings on July 31, 2025. The headline news: revenue ( GAAP ) came in at $70.0 million, which exceeded analyst expectations of $63.8 million by ...
Jul 31, 2025 • Zacks Commentary
NEUTRAL
Aurinia Pharmaceuticals ( AUPH ) Q2 Earnings Miss Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?